Tianshui Zhongxing Bio-technologyLtd's low P/E ratio is due to its poor earnings growth and the forecast of underperforming the broader market soon. The market's expected 42% growth next year, significantly outpacing the company's recent medium-term annualised growth rates, has caused shareholder discomfort and a share price drop.